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Abstract
Freezing of gait (FOG) is a distressing symptom of Parkinson’s disease with a
significant impact on fall risk and quality of life. Although medication improves some of
the symptoms of slowness and rigidity, it is only minimally effective in treating FOG.
Therefore, a better understanding of alternative treatment strategies is needed to manage
this symptom. To investigate the effectiveness of visual cueing in the management of
FOG, and to determine if visual cueing is dependent upon the spatial location of cue
presentation. Six individuals with Parkinson’s disease who experience FOG were asked to
complete the Timed Up and Go test three times in each of the following conditions: (i) no
visual cue, (ii) cue presented at the users feet, (iii) cue presented at a distance equivalent
to step length, and (iv) cue presented at a distance equivalent to stride length. Step length,
velocity, and the elapsed time taken to complete a 180 degree turn was assessed using a
10-ft Zeno electronic walkway. In addition, time taken to complete the Timed Up and Go
test was recorded, and walker positioning assessed via Kinovea motion analysis software.
The results of this study identified that irrespective of the spatial location of cue
presentation, visual cueing led to an improvement in four out of the five outcome
measures (timed up and go, turn time, walker positioning and step length). Findings from
this study may help lead to the development of best practice guidelines for implementing
this novel treatment strategy.
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Chapter 1: Introduction
Parkinson’s Disease
First described in 1817 by James Parkinson (Parkinson, 2002) and later formally
labeled by Jean-Martin Charcot (Jankovic, 2008), Parkinson’s disease (PD) is one of the
most common movement disorders in the world (Samii, Nutt, & Ransom, 2004), affecting
over 100,000 Canadians (Parkinson Society Canada, 2011). The average age of onset is
estimated to be early to mid 60’s (Inzelberg, Schectman, & Paleacu, 2002), with a higher
prevalence in males than females (Bower, Maraganore, McDonnell, & Rocca, 1999). The
frequency of PD increases with age, making the number of PD diagnoses more prevalent
within the current ageing population (Lees, Hardy, & Revesz, 2009; de Rijk et al., 1995).
Clinically, PD is a progressive neurodegenerative disorder distinguished by
bradykinesia (reduced speed of voluntary movement), resting tremor, postural instability
and rigidity (Benatru, Vaugoyeau, & Azulay, 2008). Although motor symptoms
dominate the clinical presentation, non-motor symptoms including but not limited to
depression, anxiety, and sleep disturbance, are also believed to affect the majority of
individuals at some point during the course of the disease (Aarsland et al., 2009).
Parkinsonian symptoms result from a degeneration of dopamine producing neurons
within the substantia nigra pars compacta of the basal ganglia (Damier, Hirsch, Agid, &
Graybiel, 1999). Following cell loss, the reduced dopamine levels lead to diminished
function of the basal ganglia (Bloem, Hausdorff, Visser, & Giladi, 2004), a collection of
nuclei that are responsible for regulating motor control as well as the initiation and
termination of voluntary movements (ten Donkelaar, 2011).

1

Along with degeneration within the basal ganglia, there is evidence of widespread
damage throughout the central nervous system including the autonomic nervous system,
spinal cord, olfactory region, limbic cortex, locus coerulus (norepinephrine neurons), and
nucleus basalis of meynert (cholinergic neurons) (Sethi, 2008). Although the role of
neurotransmitter depletion including acetylcholine, serotonin and noradrenaline is not yet
fully understood, Macphee & Stewart (2012) propose that the decrease in
neurotransmitters could be partially responsible for the expression of non-motor
symptoms.
While the etiology of PD remains largely unknown, evidence suggests that a
combination of factors including both genetic and environmental are involved (Samii et
al., 2004; Lees et al., 2009; Nuytemans, Theuns, Cruts, & Van Broeckhoven, 2010;
Singleton, Farrer, & Bonifati, 2013). A recent review of the literature reported mutations
in α-synuclein (SNCA), and Leucine-rich repeat kinase 2 (LRRK2) cause autosomal
dominant forms of PD, whereas mutations in parkin (PARK2), PTEN-induced putative
kinase 1 (PINK1), and DJ-1 (PARK7) lead to autosomal recessive forms of PD (Singleton
et al., 2013). Interestingly, Nuytemans et al. (2010) identified that only 15 to 20% of
individuals with PD have a clear family history of PD, thus suggesting that the etiology of
PD is a combination of multiple genetic and environmental factors (Nuytemans et al.,
2010).
From an environmental perspective, evidence suggests that certain types of toxins
elicit degeneration of dopaminergic neurons. For example, Brooks, Chadwick, Gelbard,
Cory-Slechta, & Federoff (1999), found a strong correlation between the incidences of
PD and continued exposure to paraquat - one of the most widely used herbicides in the
world. In their investigation, Brooks et al. (1999), systematically administered the
2

herbicide to mice and documented a decrease in the dopaminergic neurons of the
substantia nigra, as well as a demonstration of PD like symptoms including rigidity and
tremor (Brooks et al., 1999). Similarly, a review by Bové, Prou, Perier, & Przedborski
(2005), examined four neurotoxins (6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl1,2,3,6- tetrahydropyridine (MPTP), rotenone, and paraquat) and concluded that each
substance was capable of producing selective damage to the dopamine producing neurons.
Epidemiological studies have also implicated agents such as well water (Koller et al.,
1990), metals including manganese and iron (Zayed et al., 1990), and prolonged pesticide
exposure (Priyadarshi, Khuder, Schaub, & Priyadarshi, 2001).
There is currently no diagnostic test to confirm PD, thus diagnosis is established
based on clinical observations (Jankovic, 2008). Specifically, in order to be diagnosed
with PD an individual must present with bradykinesia and at least one of the other
cardinal features - resting tremor, postural instability, or rigidity (Tolosa, Wenning &
Poewa, 2006). Bradykinesia, the hallmark indicator is verified through demonstration of
slowness during gait, speech or expression of emotion, and/or the progressively decreased
speed with which individuals complete finger or foot tapping tests (Lees et al., 2009). The
most common assessments to classify stage and progression of the disease is the use of
the Modified Hoehn and Yahr scale, (Jankovic, 2008) and the Unified Parkinson’s
Disease Rating Scale (UPDRS) respectively (Goetz et al., 2003).
Clinical Features of Parkinson’s Disease
In addition to the primary motor features of PD previously addressed (tremor,
rigidity, bradykinesia, and postural instability), individuals with PD may experience
several secondary motor complications. These secondary features include: stooped
posture, dystonia, festination, freezing of gait, impaired fine motor dexterity, hypophonia,
3

difficulty swallowing, sexual dysfunction, micrographia, and hypomimia (Jankovic, 2008;
Lees et al., 2009; Yarnall, Archibald, & Burn, 2012). These symptoms vary in severity
and do not present universally among all individuals (Jankovic, 2008).
While the cardinal motor features of PD dominate the clinical presentation, many
individuals with PD also experience several non-motoric concerns. These may include
fatigue, anxiety, sleep disturbance, constipation, bladder and gastrointestinal disturbance,
and sensory complaints such as pain, numbness, tingling, and burning in the limbs
(Jankovic, 2008, Fahn, 2003). Behavioural and mental symptoms are also common
among individuals with PD and may include changes in mood such as depression,
decreased motivation and apathy, slowness in thinking, and dementia (Jankovic, 2008;
Fahn, 2003). In fact, recent research has identified that individuals with PD report that
non-motoric concerns are just as troubling, if not more so than some of the motor
symptoms faced by this clinical population. For example, in 2010, Politis et al., asked 265
individuals with PD to rank order their most troublesome symptoms. Individuals early in
the disease course (diagnosed within the previous 6 years) identified that slowness,
tremor, stiffness, pain and loss of smell/taste were most troublesome, whereas individuals
with more advanced PD (living with PD for ≥6 years) reported that fluctuating response
to medications, mood changes, drooling, sleep problems, and tremor were most
bothersome (Politis et al., 2010). These findings are further supported by research that
identified that Health Related Quality of Life (HRQOL), which is from the patient’s
perspective, decreases with disease progression and is impacted by more than just the
movement interruptions associated with PD (Karlsen, Tandberg, Arsland, & Larsen,
2000). For example, Forsaa, Larsen, Wentzel-Larsen, Herlofson, & Alves, (2008)
followed 227 individuals with PD over 8 years to assess levels of HRQL in relation to
4

disease progression. Although decline in physical function was reported to be the single
most important factor contributing to decreased HRQL, collectively cognitive non-motor
aspects such as loss of friends, isolation, depression, loss of independence and other
emotional consequences, surpassed the impact of motor function on levels of HRQL
(Forsaa et al., 2008). Similarly in a community based cross sectional study, Schrag,
Jahanshahi, & Quinn, (2000) concluded that individuals with PD differed most from an
age matched population in areas relating to limitations in social and physical function, as
well as in perceptions about health status, both of which were found to be associated with
a significantly impacted HRQL (Schrag et al., 2000).
Postural instability and freezing of gait (FOG) are two phenomena that have been
reported to impact negatively on an individual’s independence and ability to actively
engage in meaningful occupations (Giladi, Kao, & Fahn, 1997, Lindholm, Hagell,
Hansson, & Nilsson, 2014). Specifically, these gait impairments are most troubling as
they lead to an increased risk of falls and/or increased anxiety associated with fear of
falling (Lindholm et al., 2014). Wood, Bilclough, Bowron, & Walker (2002) conducted a
prospective study with 109 individuals with idiopathic PD and identified that following a
year of observation, falls were documented to have occurred in 68% of participants and
over 50% of these individuals fell on more than one occasion. This is not surprising as
when compared to other medical conditions, PD has been found to be the leading cause of
falls in the elderly (Teno, Kiel, & Mor, 1990). Specifically, the risk of falls and near falls
in PD compared to the general population has been reported to be two and threefold
respectively (Teno, et al., 1990; Wood et al., 2002). As a result of the gait and balance
impairments, including a stooped forward posture, falls within this population occur most
frequently in the anterior or lateral directions (Bloem et al., 2004). Unfortunately, forty to
5

sixty-five percent of falls in PD have been reported to lead to injury, and over seventyfive percent of these injuries require healthcare services (Gray & Hildebrand, 2000;
Wielinski, Erickson-Davis, Wichmann, Walde-Douglas, & Parashos, 2005). The
increased risk of falls associated with PD is particularly important not only because of the
propensity for injury, but also because of the fear and anxiety related to decreased
functional mobility that ultimately contributes to a loss of independence, increased risk of
depression, and a reduced quality of life (QoL) (Moore, Peretz, & Giladi, 2007; Bloem et
al., 2004; Benatru et al., 2008; Lindholm et al., 2014).
Fear of falling (FOF), recognized as the anxiety related to the fear of future falls,
impacts QoL such that it is the major factor contributing to self-imposed activity
restriction (Rahman, Griffin, Quinn, & Jahanshahi, 2011; Murphy, Williams, & Gill,
2002). The phenomenon originates as a feeling/thought, but as an individual’s confidence
in their physical ability decreases, FOF limits daily activities and becomes a real/tangible
problem (Perez-Jara, Walker, Heslop, & Robinson, 2010). Typically, individuals with a
heightened FOF either tend to rely more heavily upon others to accomplish basic tasks or
else they avoid situations all together thus leading to social isolation and depression. As a
result, caregivers may experience a larger burden resulting from increased demands being
placed upon them, or a greater need for home based care, consequently posing an
economic burden on society (Perez-Jaraet al., 2010). Rahman et al., (2011) evaluated 130
individuals with PD to identify factors associated with FOF. Gait disturbances such as
FOG, as well as advanced disease progression were reported to lead to greater levels of
FOF. In their study FOF was quantified via three questionnaires (Falls Efficacy Scale,
Consequences of Falling, and Survey of Activities and Fear of Falling in the Elderly), and
accounted for 65% of the variation in QoL scores, thus indicating that FOF is a significant
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factor that warrants consideration when dealing with individuals with PD (Rahman et al.,
2011).
Management of Symptoms
While there currently remains no cure for PD, advances in the pharmaceutical
industry have resulted in treatment being focused on symptom management and geared
towards maintaining independence and QoL (Lees et al., 2009). Specifically, Levodopa
was developed in the late 1960’s and was the first pharmaceutical proven to be effective
in the treatment of PD (Cotzias, Papavasiliou, & Gellene, 1969). Surprisingly, since its
development, Levodopa remains the single most efficacious medication (Schapira, Emre,
Jenner & Poewe, 2009; Zappia, Colosimo, & Poewe, 2010). Although Levodopa
replacement therapy leads to clear improvements in motor symptoms such as
bradykinesia and rigidity (Lees et al., 2009), after approximately 5 years of beginning
treatment, 50% of individuals taking Levodopa develop motor complications including
wearing off and dyskinesia’s (involuntary uncontrolled movements) (Kumar, Van Gerpen,
Bower, & Ahlskog, 2005; Mazzella, et al., 2005; Rascol et al., 2000). To help delay the
onset of these motor complications and to help ensure that the drug remains effective as
the disease progresses into the more advanced stages, pharmacological management often
begins with the administration of dopamine agonists (Hubble, 2002). While dopamine
agonists have the advantage over Levodopa in that they do not cause dyskinesia’s, they
are however believed to be between 10%-20% less effective (Parkinson Study Group,
2000; Lees, Katzenschlager, Head, & Ben-Shlomo, 2001; Rascol et al., 2000), and are
associated with additional side effects including dizziness, hallucinations, and nausea
(Tuite & Ebbitt, 2001).
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While medication has been found to improve some of the symptoms of PD such as
bradykinesia, rigidity, and tremor, it has been found to be only partially effective in
managing FOG (Bowes et al., 1990; Levy-Tzedek, Krebs, Arle, Shils, & Poizner, 2011).
For example, Sethi (2008) examined the literature on the effectiveness of Levodopa in
managing FOG and identified in general that positive effects of Levodopa treatment were
reported in studies that included participants early in the disease process, whereas FOG
was more apt to be unresponsive to Levodopa treatment among individuals in more
advanced stages of the disease. The results of this review suggested that the observed
benefits might have been attributed to improvements in rigidity and bradykinesia as
opposed to a direct effect on FOG (Sethi, 2008).
Freezing of Gait
Freezing of gait (FOG), also known as a motor block, is a type of gait disturbance
commonly associated with the later stages of PD (Giladi et al., 2001). Described by
individuals as feeling like their feet are glued to the floor (Browner & Giladi, 2010), FOG
is defined as a temporary hesitation or inability to initiate normal gait (Rahman, Griffin,
Quinn, & Jahanshahi, 2008, Contreras & Grandas, 2012). Triggers that commonly induce
freezing episodes include initiating movement, turning, approaching obstacles or
doorways, as well as emotional factors such as stressful situations or fatigue (Contreras &
Grandas, 2012; Lamberti et al, 1997; Rahman et al., 2008). Performing more than one
task at a time (i.e., dual or multi tasking), or ambulating in situations that place increased
attentional demands on the individual (i.e., walking in a crowded mall), have also been
reported to elicit FOG (Rahman et al., 2008). Interestingly freezing episodes may also
occur spontaneously in absence of FOG-provoking stimuli (Schaafsma et al., 2003). One
possibility that may account for spontaneous FOG is offered by Nieuwboer et al., (2001)
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who suggests that FOG while walking may stem from failure to generate normal
amplitude in step length. This possibility is supported by Chee, Murphy, Danoudis,
Georgiou-Karistianis, & Iansek (2009) who reported an increased frequency of FOG with
reduced stride length and a gradual step-to-step reduction, called a sequence effect.
While the pathophysiology of FOG remains unknown, it is well established that
the frequency of freezing episodes increases with disease duration with up to 80% of
individuals experiencing episodes during the more advanced stages of the disease (Macht
et al., 2007). Similarly, although much remains unknown about FOG, it is clear that the
consequences of this motor symptom are severe. For example, not only does FOG affect
the independence of individuals living with PD because of its propensity to cause falls
(Bloem et al., 2004), but this phenomena leads to a significantly reduced QoL (Giladi et
al., 2001). Moore et al. (2007) examined how the severity of FOG impacted QoL within
individuals with PD, through the use of self-reports and questionnaires. They concluded
that the unpredictable nature of FOG was one of the main factors in reducing QoL. FOG
is a source of embarrassment and frustration when an individual seemingly loses control
over basic functions, such as walking, and these emotional costs were most significantly
related to decreased QoL. The importance of treating this highly visible and sometimes
embarrassing symptom, as well as understanding its causes are critical for improving
patient QoL (Michalowska, Fiszer, Krygowska-Wajs, & Owczarek, 2005; Moore et al.,
2007).
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Management of Freezing of Gait
While pharmacological management has proven to be an effective strategy in
mitigating some symptoms of PD, it has minimal effects on improving postural stability
(Bloem, 1992) and in fact has in some cases been found to exacerbate FOG symptoms
(Bloem et al., 2004; Lamberti et al., 1997). For example, Contreras & Grandas (2012)
conducted a cross sectional study to determine the risk factors involved in FOG. One
hundred and sixty individuals (both males and females) of, varying ages and disease
duration were compared to assess differences between those with and without FOG.
Results indicated that on average subjects who experienced FOG were taking a
significantly higher dose of Levodopa (474.6 vs. 650.1mg/day). Moreover of the 44% of
individuals who experienced FOG, 35% experienced freezing episodes during the “on”
phase of their medication cycle. As a result of the limited effectiveness of medications to
manage FOG and postural instability, many individuals with PD require the use of
assistive devices such as a walker to help maintain their mobility in the later stages of the
disease. Although the utilization of walker’s are beneficial in that they provide a stable
base of support and a sense of security for users, they also significantly reduce walking
speed (Cubo, Moore, Leurgans & Goetz, 2003). Cubo et al. (2003) examined the gait
patterns of individuals with PD with and without the use of standard and wheeled walkers
under conditions known to elicit FOG. Findings indicated that gait speed decreased for
each trial involving either type of walker, and that the number and length of freezing
episodes increased in trials involving the standard walker (Cubo et al., 2003).
A second factor that bares consideration when dealing with the use of walkers is
that of their impact on posture. Research conducted by Liu (2009) assessed the usage of
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rolling walkers by 158 older adults identified that as many as 50% of participants adopted
a forward leaning posture while ambulating with the walker. This common problem
among walker users is known to increase the potential for falls (Liu, 2009), thus coupled
with the characteristic stooped posture associated with PD, the risk for falls would likely
be even greater in this population. Thus, while walkers provide support to help minimize
falls during episodes of freezing, they also have an effect on spatiotemporal parameters of
gait that may consequently exacerbate the very phenomena they were designed to assist
with. One strategy that has been found to help normalize gait among individuals with PD
is to use external cues.
External Cues
External cueing is one strategy that has emerged as a promising nonpharmacological option to help normalize gait patterns and manage FOG (Bloem et al.,
2004). External cues can be presented in the form of tactile, auditory, and visual
information that can trigger movements or provide rhythmic or spatial support to improve
the quality of movements (Rochester et al., 2005). Cueing is believed to work by evoking
increased sensory stimulation thus directly focusing attention on the gait task, therefore
shifting the locus of control from the automatic control of the basal ganglia to other
conscious pathways.
Tactile Cueing
While impairment of the motor system (basal ganglia and motor cortex) is
traditionally considered to be the major cause of conventional parkinsonian gait (Bartels,
& Leenders, 2009), increasing evidence suggests that sensory abnormalities may also be
responsible (Labyt, et al., 2013). Specifically, it has been proposed that impaired central
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sensorimotor integration at the striatum and defective peripheral sensory proprioceptive
feedback may contribute to abnormal movement in PD (Abbruzzese & Berardelli, 2003;
Lewis, & Byblow, 2002). This is a particularly interesting finding given that among
individuals without neurological disease, decreased peripheral sensation achieved by
anesthesia of the foot sole has been demonstrated to impair static and dynamic balance
control (McKeon & Hertel, 2007; Meyer, Oddsson, & De Luca, 2004). Conversely,
sensory stimulation of the plantar cutaneous surface in elderly subjects has been shown to
improve balance and gait (Maurer, Mergner, Bolha, & Hlavacka, 2001). Similar
improvements have also been reported among individuals with PD. For example, Novak
& Novak (2006) assessed the effects of enhanced proprioceptive feedback using step
synchronized vibratory insoles among 8 individuals with mild-moderate PD (Novak, &
Novak, 2006). Results demonstrated that when the vibratory insoles were worn,
improvements were noted in stride length, velocity, cadence, and stride variability.
Improvements to gait have also been demonstrated using a shoe insole with a raised ridge
near the perimeter of the sole (Jenkins et al., 2009). Results demonstrated that among 40
individuals with mild PD, single limb support time and velocity both increased with use
of the facilitatory insole. Furthermore, use of the insole resulted in an improvement in the
timing of tibialis anterior muscle activation during the heel strike phase of gait, leading to
improvement in the gait pattern (Jenkins et al., 2009). While results are encouraging,
proprioceptive insoles of this nature have yet to become commercially available. In
addition, some consideration must be given to the use of this form of cueing over a
longitudinal time period as this may elicit potential risks associated with skin breakdown,
especially among individuals with reduced circulation.
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Researchers have also investigated the use of both auditory and visual cueing as
means of improving gait among individuals with PD (Suteerawattananon, Morris, Etnyre,
Jankovic, & Protas, 2004). Glickstein & Stein (1991) suggest that these types of external
cues make use of a patients cerebellar pathway which is unaffected by PD. For example,
in cases where visual cues are adopted, movements are directed by vision as opposed to
the basal ganglia, which is usually involved in motor control, effectively bypassing the
disease affected region of the brain (Glickstein, & Stein, 1991).
Auditory Cueing
To date, several different types of auditory cueing have been investigated and
include strategies such as listening to the beat of a metronome, or listening to the rhythm
of music. For example, Willems et al., (2006) examined the influence of auditory cueing
among 20 individuals with PD. Auditory cues in the form of a metronome beat were
administered as participants walked along an 8 m long walkway. Results indicated that
while all participants benefited from receiving rhythmic auditory cues in relation to step
frequency (steps/minute) and speed, cueing had minimal impact on step length.
Spildooren et al., (2012) also investigated the effects of using a metronome to improve
gait among 30 individuals with PD classified as either non-freezers (n=14) or freezers
(n=16). Unlike previous research wherein auditory tones are provided to cue each step,
Spildooren et al., (2012) examined the utility of cueing each stride - an approach that was
termed unilateral cueing. Similar to the findings of Willems et al., (2006), Spildooreen et
al., (2012) identified that rhythmic auditory cueing serves as a useful strategy for
managing FOG. Specifically, results demonstrated that cueing significantly decreased
episodes of FOG, as freezing occurred in 53.8% of trials during baseline compared with
only 3.8% during cued trials.
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Rhythmic auditory stimulation delivered in the form of a music stimulus has also
been reported to lead to significant improvements in spatiotemporal parameters of gait.
For example, Thaut et al., (1996) investigated the effects of a 3 week home based gait
training program focused on improving mobility via auditory music cueing among 15
individuals with demonstrated gait impairment secondary to PD. In their investigation,
the auditory cues consisted of audiotapes with metronome-pulse patterns embedded into
the on/off beat structure of rhythmically accentuated instrumental music. Results
established the effectiveness of this intervention as the musical cues were found to
significantly improve participants gait velocity by 25%, stride length by 12%, and step
cadence by 10%. Furthermore, timing of muscle activation patterns for the tibialis
anterior and vastus lateralis were found to improve on trials involving the rhythmic
stimuli (Thaut et al., 1996).
While the effectiveness of using rhythmic auditory cues to improve gait among
individuals with PD is promising, application of auditory cues may pose a practical
problem in day-to-day situations. For example, to deliver an external auditory cue outside
of a controlled setting requires the use of headphones. This has the potential to interfere
with an individual’s ability to interact with their environment and could become a hazard
when navigating crowded public areas. For example, Brown, Bruin, Doan, Suchowersky,
and Hu (2009) identified that listening to music while walking may be detrimental to ones
safety as this places the individual in a dual-task situation wherein they may have their
attention divided. As a result of this divided attention, individuals may have less cognitive
resources available (Grimbergen, Dijk, Munneke, & Bloem, 2006) thus diminishing their
capacity to navigate their environment safely. In addition, listening to repetitive tones
such as those produced by a metronome may become quite monotonous, and may lead to
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diminished efficacy of the intervention over time as a result of habituation.
Visual Cueing
To date, studies have evaluated the effect of visual cues on gait among individuals
with PD in both laboratory and home settings, and have provided evidence of short-term
treatment fidelity. In fact, research suggests that visual cueing is the most effective form
of cueing modality. For example, Rahman et al., (2008) surveyed 130 individuals with
PD regarding the cues and strategies that help them overcome episodes of FOG. The
results revealed that 31.5% of the sample reported that visual cues improved their
mobility, whereas tactile and auditory cueing were effective to a lesser extent with 27.7%
and 19.2% of the sample reporting these cues to be effective, respectively. The most
common visual cues that have been investigated include transverse lines marked on the
floor, and the use of various forms of laser lights. For example, Morris, Iansek, Matyas,
and Summers (1996), examined the effects of using visual floor markers on the walking
pattern of 54 individuals with PD. Their results demonstrated that the ability to generate a
normal stepping pattern is not lost in PD as evidenced by the ability of participants to
elicit normal stride length when using the visual cues. Similar findings were also
reported by Jiang and Norman (2006) who observed that visual cues were effective at
improving gait among 14 individuals with PD. The visual cues used were high contrast
transverse lines on the floor and were found to result in increases to both pace and stride
length. More recently, Lee et al. (2012) used both visual and auditory cues as a means to
discern their effects as a possible treatment for FOG in 15 individuals with PD troubled
by FOG. The visual stimuli presented were evenly spaced transverse white lines placed
along a walkway corresponding to set distances of a normalized step length for each
subject, and the auditory cue was a rhythmic tone created by a metronome. Results
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indicated that both visual and auditory cues significantly increased velocity and stride
length, and reduced both cadence and number of freezing episodes as compared to
baseline. While both visual and auditory cues were able to positively affect parameters of
gait, when the two forms of cueing were compared, visual cueing was found to lead to
improvements that were significantly greater than those obtained with the auditory cue
(Lee et al., 2012).
Although significant improvements are realized when using visual cues such as
transverse lines on the floor, there is a considerable limitation with adopting this approach
in a community setting. For example, while it may be possible to design the home
environment to support a visual cueing approach using transverse lines on the floor, this
would not be possible to do for all venues visited outside of the home. As a means to
overcome this limitation, In Step Mobility Products Inc, launched an, innovative walker
called the U-Step. The U-step walking stabilizer is a specialized walker prescribed to
many individuals with gait and balance problems. In particular, individuals with PD
benefit from the U shaped frame that provides support in many directions and increases
stability. While similar in design to other wheeled walkers, the U-Step is unique in that it
contains a built in cueing device that emits a laser beam of light on the ground (In Step
Mobility, 2009). This transverse line of light progresses with the walker and acts as a
dynamic stimulus that can be stepped over, thus promoting effective ambulation much the
same way in which the static transverse stripes function.
Donovan et al. (2011) assessed the efficacy of the U-Step walker and visual cue
for overcoming FOG within a sample of 26 individuals with PD. Participants were first
provided the opportunity to become familiar with the walker without the visual cue turned
on over a 1-2 month baseline period, following which they were instructed to use the
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walker for an additional month with the laser light turned on during ambulation. Results
indicated that the visual cue lead to improvements in gait as demonstrated by a mean
improvement of 6.6% on the freezing of gait questionnaire. Specifically, secondary
analyses of the individual items that comprised the freezing of gait questionnaire
indicated the laser cue resulted in a significant reduction in both the number of freezing
episodes experienced and the duration of start hesitations as compared to values at
baseline.
Kegelmeyer, Parthasarathy, Kostyk, White, and Kloos (2013) also investigated the
utility of the U-Step walker to improve gait among 27 individuals with PD. In their
investigation, spatiotemporal parameters of gait were examined as participants walked in
both a straight path and around obstacles. Similar to the findings of Donovan et al. (2011),
the U-Step walker was found to lead to improvements in gait patterns including increased
velocity, and a decrease in the incidence of freezing episodes. It is important to note,
however, that the U-Step walker was also found to produce significant variability in gait,
a factor known to be associated with falls (Shaafsma et al., 2003). The authors suggest
that the increased variability may be the result of several design factors including added
walker weight, a reverse braking system, and the requirement for participants to look
down at the ground to see the laser. In addition, results indicated that the laser light on the
U-Step walker did not improve gait measures or safety when participants walked around
obstacles. This finding is not surprising, given the research conducted by Patla (1998),
and Marigold & Patla (2007, 2008) on the importance of fixating visual gaze ahead of
oneself to assist with obstacle avoidance and planning subsequent foot placement.
Given the aforementioned literature on the importance of directing visual gaze
ahead of oneself, a limitation of the U-Step walker is that the visual laser cue is directed
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towards the ground between the rear wheels. As a result, when individuals use the visual
cue they must focus their attention downwards, preventing them from looking ahead. In
addition to disrupting visual gaze, this action encourages individuals to adopt a forward
flexed posture. This is important, especially for individuals with PD who already manifest
a stooped posture and compromised postural reflexes that place them at an increased fall
risk (Latt, Lord, Morris, & Fung, 2009; Liu, 2009). A second limitation associated with
the U-Step is that it has a prominent heavy frame that is not aesthetically pleasing and
cannot be customized to suit the user’s preferences (e.g., restricted colours available). The
limited options the U-Step provides along with frame design can lead to embarrassment
and feelings of being socially unacceptable that in turn may result in diminished
adherence or device abandonment (Parette, & Scherer, 2004).
In lieu of the aforementioned limitations, a company named ProtoKinetics
developed a portable laser cue named the Mobilaser. This device is innovative in design
as the laser cue is emitted from an extension that swivels thus serving as an adjustable
visual cue (MAP/CIR Inc., 2011). As a result of this articulating portable design, the
device is able to be attached to any assistive mobility device of the user’s choice and the
articulating head can be adjusted as to properly align the visual cue while the device is
mounted in various positions specific to the frame design of each walker. In a recent cross
over study, Van Gerpen, Rucker, Matthews, & Saucier (2012) examined the Mobilaser
while attached to a wheeled walker to determine its effects on the occurrence of FOG and
time taken for 6 individuals with Parkinsonism to complete a predetermined course. As
opposed to the fixed traditional laser, which projects a line of light near the users feet,
Van Gerpen et al. (2012) utilized the adjustability of the Mobilaser to project the laser
line approximately where each person’s next step would fall. Although this placement is
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similar to the traditional cue location (e.g., within the walker frame near the rear wheels)
it allows for customization to accommodate varying user heights. The study was
conducted in a realistic environment and the testing protocol required subjects to walk a
course that involved exiting a doorway, turning right, walking down a hallway, turning
around, and returning to the doorway. Analyses revealed that the Mobilaser produced a
significant reduction in the number of freezing episodes and resulted in faster times
walking the course compared to when the wheeled walker was used without the visual
cue.
As briefly mentioned previously, one limitation to the aforementioned visual
cueing approach is that both the U-Step walker and Mobilaser TM require users to direct
their attention downward to the ground immediately in front of their feet. This is
important because research has identified that when vision is limited to less than 2 step
lengths ahead of someone as they walk, their walking speed decreases and they
experience more frequent collisions with obstacles (Matthis & Fajen, 2013). Specifically,
vision is critical for control of safe movement as it provides information regarding stepto-step progress as well as incorporating environmental conditions into route planning
(Patla, 1997, 1998). Moreover, vision allows for avoidance strategies to be implemented
and for accurate step placement that helps maintain balance during locomotion (Patla,
1997; Marigold & Patla, 2007). For example, Marigold and Patla (2007) investigated
walking across varied types of terrain while recording gaze fixation and identified that
individuals spent 56% of the time with their visual gaze fixated roughly two steps ahead.
This strategy of fixating visual gaze ahead of oneself serves to allow a large amount of
peripheral vision to remain available within the lower visual field. This is important as the
information obtained from the lower visual field is used to control gait, and is particularly
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important for obstacle avoidance and planning subsequent foot placement (Patla, 1998).
A follow up study conducted by Marigold and Patla (2008), examined the impact of
obstructing the lower visual field on spatiotemporal parameters of gait and identified that
gait speed and step length became significantly reduced in trials wherein the lower visual
field was obstructed compared to those when vision was unobstructed.
Provided that both the U-Step walker and Mobilaser TM require users to direct their
visual gaze downward towards the ground immediately in front of their feet, individuals
who adopt these devices are likely less able to pay attention to the environment ahead of
them. As a result, it is possible that these individuals are at an inherent risk of colliding
with an object that may subsequently precipitate a trip or a fall (Matthis & Fajen, 2013).
Taken together with research indicating that both using a walker (Cubo et al., 2003) and
directing visual gaze less than 2 step lengths ahead (Matthis & Fajen, 2013) results in
diminished spatial temporal parameters of gait, and with research illustrating that FOG
may be exacerbated by decreased spatial temporal parameters of gait (Cubo et al., 2003);
a logical next step in this line of inquiry would be to determine whether the efficacy of
visual cueing is dependent upon the spatial location of cue presentation. Specifically,
stemming from the research conducted by Patla, (1998) and Marigold & Patla, (2007),
research is needed to determine whether visual cueing remains an effective strategy to
improve gait among individuals with PD when the visual cue is directed ahead of the user
instead of in the traditional spatial location at their feet.
As a first step in this process, initial feasibility testing is required. Therefore, the
purpose of this investigation was to conduct a feasibility study to test study protocol and
elucidate pragmatic indicators that will need to be considered in the design of a future
full-scale study intended to investigate the effect of spatial location on visual cue
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effectiveness. Specifically, the objectives of this feasibility study were twofold: i) to test
the study protocol and outcome metrics (i.e., effectiveness of recruitment strategy,
visibility of visual cues, levels of protocol compliance), and, ii) to determine whether
there are preliminary indications that the intervention involving a more forward placed
visual cue will be successful and thus worth pursuing (i.e., examine trends).
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Chapter 2: Methods
Recruitment Strategy and Sample
A purposive sample of 6 participants with idiopathic Parkinson’s disease (PD),
with a history of freezing of gait (FOG) and falls, were recruited for this study.
Recruitment of participants and confirmation of PD diagnosis based on established
diagnostic criteria (Hughes, Daniel, Kilford, & Lees, 1992), were completed by a
neurologist specializing in movement disorders from a clinical practice in London,
Ontario.
In order to be eligible to participate, individuals were required to: i) be at least 50
years of age, ii) have a clinical diagnosis of PD with a history of FOG and falls, iii) be
capable of walking 20 feet with or without the use of an assistive device, and iv) have
functional vision that allowed them to see the visual cue (laser beam of light projected on
the ground). Individuals were excluded from participating if they reported experiencing
major back or lower limb pathology that may influence gait, or if they were unable to
perceive the visual cue.
Testing Protocol
Testing for each participant was completed in a single session held within the
Interdisciplinary Movement Disorder Laboratory, located in Elborn College at The
University of Western Ontario. At the beginning of the testing session each participant
received a copy of the letter of information to review (Appendix A), had all aspects of the
study verbally explained to them, and were provided with an opportunity to ask any
questions. Once all questions were answered to their satisfaction, participants were asked
to provide informed written consent (Appendix B). The research protocol, recruitment
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method, and mechanism for obtaining informed consent were approved by the Health
Sciences Research Ethics Board, at The University of Western Ontario (Appendix C).
Upon providing informed consent, participants received a brief clinical
examination by the study neurologist to determine disease severity. Specifically
participants were assessed on the motor subscale (subsection III) of the Unified
Parkinson’s Disease Rating Scale (UPDRS-III; Appendix D) and on the modified Hoehn
& Yahr staging scale (H&Y; Appendix E). Subsection III of the UPDRS was used to
describe a participant’s motor function by assigning a value of 0 to 4, within several
domains related to: bradykinesia, postural stability, gait, rigidity, tremor and speech.
Within the UPDRS, a score of 0 indicates normal function, whereas a score of 4 indicates
severe presence of the symptom (Movement Disorder Society, 2003). Subsection III is
scored out of 56, with a higher overall score being indicative of greater disease severity.
The UPDRS is a widely used evaluation tool shown to have high inter-rater reliability
(The total sum of all UPDRS motor scores, ICC = 0.82) (Richards, Marder, Cote, &
Mayeux, 1994).
The modified Hoehn & Yahr Staging scale is a tool that was developed to describe
how the symptoms of PD progress. The scale is comprised of an 8 stage rating system
that ranges from 0 through 5 where a score of 0 represents the absence of disease signs,
whereas a score of 5 represents significant progression wherein the individual is
wheelchair or bedridden unless aided (Goetz et al., 2004). The modified Hoehn & Yahr
scale is an expanded version of the original six level scale developed by Hoehn and Yahr
in 1967 (Hoehn & Yahr, 1998).
Each participant was also asked to fill out a Freezing of Gait Questionnaire (FOGQ). The FOG-Q is a self-report survey consisting of six questions that subjectively
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assesses the severity and frequency of FOG (Giladi et al., 2000). For each question, the
respondent is asked to assign a value of 0 to 4 regarding different aspects of FOG or gait
disturbance. The cumulative total of these values range from 0-24, with a higher overall
score corresponding to more severe the FOG. This questionnaire has been shown to have
excellent intrarater reliability (ICC = 0.84) (Nieuwboer et al., 2007), and excellent testretest reliability (r = 0.84) (Giladi et al., 2009) in people with PD. Participants’
demographics are presented in Table 1.

To ensure participant safety, each participant was placed in a balance support
harness system (SoloStepTM) consisting of a support vest attached to an overhead rail
(Figure 1). To ensure a proper fit and to help participants become accustomed to the
harness system, participants were asked to walk to the end of the room, turn, and walk
back (approximately 20 feet). Next, participants completed a series of 12 videotaped
walking trials using a wheeled walker instrumented with a laser cueing device (i.e.,
Mobilaser) (Figure 2). Specifically, participants were asked to complete 3 walking trials
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under each of the following four conditions: (i) no visual cue (Baseline), (ii) visual cue
projected between the centre of the rear wheels of the walker (traditional cue placement),
(iii) visual cue projected at a distance equivalent to mean sex specific step length (Male =
62cm, Female = 60cm) in front of the centre of the rear wheels (step length), and (iv)
visual cue projected at a distance equivalent to mean sex specific stride length (Male =
123cm, Female = 119cm) in front of the centre of the rear wheels (stride length) (Ko,
Tolea, Hausdorff, & Ferrucci, 2011). Each walking trial followed the protocol of the
Timed Up & Go test (TUG) as follows. Participants started in a seated position in a
standard arm chair (seat height = 45 cm), and when instructed to begin, stood up, walked
3 meters at a comfortable pace, turned around, walked back to the chair and sat down.
The time it took participants to complete the trial was recorded using an Adanac 3000®
Digital Economy Stopwatch.

Figure 1. Images of the Solo-Step TM Support System
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Figure 2. Mobilaser - Visual Cueing Device
Immediately prior to the beginning of each trial, the participant’s received one of
three sets of instructions. For trials with no visual cue (baseline), participants received the
verbal instruction “When I say go, I would like you to stand up, walk at a comfortable
pace to the end of the mat, turn around, walk back, and sit down”. For trials where the
visual cue was located between the walker rear wheels (traditional cue placement),
participants received the verbal instructions “When I say go, I would like you to stand up,
walk at a comfortable pace to the end of the mat, turn around, walk back, and sit down.
As you walk, I would like you to focus on stepping over the laser cue”. For trials where
the visual cue was located ahead of the walker rear wheels (i.e., either step length, or
stride length conditions), participants received the verbal instructions “When I say go, I
would like you to stand up, walk at a comfortable pace to the end of the mat, turn around,
walk back, and sit down. As you walk I would like you to focus on stepping towards the
laser cue”. To ensure participants understood the instructions, a single practice trial was
completed for each condition at the beginning of each block of walking trials. To avoid
practice effects, the order of presentation of the walking conditions was randomized for
each participant.
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All testing was completed while participants were on their self-determined peak,
or “on” phase, of their medication cycle. To help ensure all participants were within their
“on” phase, testing was conducted approximately two hours after participants had taken
their usual dosage as per the recommendations of Gauntlett-Gilbert and Brown (1998).
Outcome Measures
Spatial Temporal Parameters of Gait
Spatiotemporal parameters of gait for each walking trial were acquired using a 4
foot wide x 10 foot long Zeno Electronic Walkway© Model Z4x10 and ProtoKinetics
Movement Analysis Software (PKMAS) (Zenometrics LLC, Peekskill, NY, USA)
(Figure 3). Using sensor array technology, the Zeno walkway© samples gait at 120Hz
and has a spatial resolution accuracy of 1.27cm and temporal resolution accuracy of 1
sample (ProtoKinetics Movement Analysis Software, 2012). The Zeno walkway©
(formerly GaitRite) has been found to be a reliable measurement of gait parameters in this
population (Chien et al., 2006). The dependent variables included: velocity, step length,
and the time taken to complete the 180o turn at the end of the walkway. To minimize the
potential for outlying data to influence the results, trials were averaged within each
condition such that a single value was obtained for each outcome measure.

Figure 3. Zeno Electronic Walkway©
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Timed Up and Go (TUG)
Functional mobility was assessed as participants completed each walking trial via
the Timed-Up-And-Go (TUG) testing protocol under each condition. This test has been
shown to have good test-retest reliability (r = 0.80) (Huang, Hsieh, Wu, Tai, & Lu, 2011),
and high inter-rater reliability (ICC ≥ 0.87) (Morris, Morris, & Iansek, 2001) in people
with PD.
Walker Positioning
To determine if the position of the walker in relation to the participant changed as
a result of the spatial location of the visual cue presentation, all walking trials were
videotaped using a Canon PowerShot SX 220 HS camera and analyzed using Kinovea
(version 0.8.15) software. Two reflective markers (A & B) were placed in parallel on the
walker frame and one reflective marker (C) placed on the balance harness positioned over
the lateral aspect of the participants’ iliac crest. Using Kinovea, a vertical line was drawn
between markers A and B and a horizontal line drawn at a right angle from the vertical
line to marker C. The horizontal distance between the vertical line (walker) and marker C
(participant) was used to determine the relative position of the walker in relation to the
participant, an example of this configuration is shown in Figure 4.
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Figure 4. Reflective Marker Set-up (A, B, & C)
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Chapter 3: Results
Objective 1 – Study Feasibility
Recruitment Strategy
Participants were recruited from a single neurological practice over a two month
timeframe. In total, 7 individuals agreed to participate; however one of these individuals
did not meet the inclusion criteria and was therefore excluded. The six participants
recruited were highly varied across numerous demographic characteristics. For example,
the participants’ ages ranged from 62 to 86, disease duration ranged from 5 to 18 years,
and the Hoehn and Yahr scale results varied from 2.5 to 4. Specifically, the Hoehn and
Yahr results indicated that some participants were experiencing symptoms ranging from
mild bilateral disease to severe disability (Hoehn & Yahr, 1998). The level of FOG
disturbance also varied greatly among participants. This was evident from the FOG-Q
scores, which ranged from 11 to 22.
Level of Protocol Compliance
With altering the spatial location of the visual cue, it was unknown as to whether
the intensity of the visual stimulus would be strong enough for participants to clearly see
the cue when projected ahead of the walker. All participants indicated that they were able
to clearly observe the visual cue even when it was directed to the furthest position away
from the walker, - equivalent to the average stride length of an older adult (119-123cm).
With respect to trial completion, the majority of participants (4/6) were able to
complete all aspects of testing procedures. Two participants (P4, P6) were unable to
complete the testing protocol in its entirety. Both of these individuals experienced fatigue
near the end of some of the trials and required adjustments to be made to the position of
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the chair to complete the final turn of the walking trials. This was most evident with
participant 4 who experienced severe fatigue as a result of extended periods of freezing,
and was unable to complete all twelve trials.
An impact of anxiety was also exhibited by P4, who repeatedly voiced concern
regarding their performance during the walking trials. Following the initial completion of
a single baseline trial, the participant was recognizably fatigued as a result of the duration
of the trial and the occurrence of severe freezing (Figure 6d). A decision was made to
have the participant subsequently complete only a single trial of each visual cue condition.
After completing 4 trials, P4 took a 5 minute rest break and then expressed a desire to
attempt the cue conditions again. The individual completed 3 more trials (1 of each visual
cue condition) revealing a dramatic change in their performance. For example, across
each of the visual cue conditions P4 was approximately 60 seconds slower at initially
completing the TUG test, compared to the second attempt with the same cue condition.
Each testing session lasted 30-45 minutes within the lab, which included obtaining
informed consent, and trial demonstrations provided by the researchers. Due to the
relatively short length of the testing session, participants did not report experiencing any
issues with wearing off their medication over the course of the session.
Lastly, all participants were able to independently complete the FOG-Q. This is
important in terms of a future home based longitudinal follow-up study, as the FOG-Q
can be used as a measure of change that can be collected without the researcher’s
presence.
Objective 2 - Preliminary Findings
To determine whether the intervention showed promise as an effective
management strategy, spatial temporal parameters of gait were evaluated on the Zeno
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Electronic Walkway. Participants were assessed at baseline in the absence of a visual cue,
and with the visual cue positioned in each of the following spatial locations: i) between
the centre of the rear wheels of the walker (traditional cue placement), (ii) at a distance
equivalent to one step length in front of the centre of the rear wheels (step length), and (iii)
at a distance equivalent to one stride length in front of the centre of the rear wheels (stride
length). For each of the dependent variables acquired (step length, velocity, turn time,
timed up and go score, and walker positioning) comparisons were made between values
obtained at baseline (no visual cue) to those reported during each presentation of the
visual cue (baseline vs. traditional cue; baseline vs. step length; and baseline vs. stride
length). Specifically, using the statistical software package SPSS, three paired t-tests were
conducted for each of the dependent variables with alpha set at .05. As a result of multiple
comparisons being performed, it was anticipated that the potential for a Type I error to
occur would be increased, however this was a feasibility study and therefore the decision
was made not to apply bonferroni corrections. The results for each of the t-tests
associated with the respective outcome measures are presented below.
Spatial Temporal Parameters of Gait
Means and standard deviations, along with individual participant data for step
length, velocity, and turn time are presented in Table 2. For step length there were no
significant differences between baseline (M= 30.67cm, SD= 13.98) and each of the visual
cue locations: traditional cue placement (M= 38.50cm, SD= 14.27); t(5)= -2.159, p = 0.08,
step length cue placement (M= 35.33cm, SD= 17.85); t(5)= -1.075, p = 0.33, or stride
length cue placement (M= 34.17cm, SD= 18.02); t(5)= -1.069, p = 0.33. Similar findings
were also identified for velocity as there were no significant differences detected between
baseline (M= 51.17cm/s, SD= 28.91) and each of the visual cue locations: traditional cue
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placement (M=48.50cm/s, SD=8.63); t(5)=0.392, p = 0.71, step length cue placement
(M=51.33cm/s, SD= 32.02); t(5)= -0.027, p = 0.98, or stride length cue placement
(M=51.67cm/s, SD= 31.98); t(5)= -0.088, p = 0.93. Similar to the findings reported for
step length and velocity, no significant differences were identified between the length of
time it took participants to turn in the absence of a visual cue (M= 20.17s, SD= 25.96)
compared to when they used a visual cue irrespective of cue location: traditional cue
placement (M= 7.83s, SD= 3.71); t(5)= 1.312, p = 0.24, step length cue placement (M=
12.67s, SD= 14.35); t(5)= 0.802, p = 0.45, or stride length cue placement (M= 15.17s,
SD= 16.53); t(5)= 0.722, p = 0.50.
Although results for each of the variables were statistically non-significant, results
suggest the presentation of visual cues did have an impact on spatiotemporal parameters
of gait for some participants (Table 2 and Figures 5a - 5c and Figures 6a - 6f). For
example, with the Mobilaser turned on, 5 out of 6 participants’ demonstrated increases to
step length, and 3 out of 6 participants demonstrated increases to velocity and decreases
to turn time. While on the individual level the utilization of the visual cue lead some
participant’s to experience substantial improvement (i.e., step length for participant 3
increased from 41cm at baseline to 66cm with the cue projected at step length) whereas
other individuals only experienced marginal gains (i.e., step length for participant 5
increased from 37cm, at baseline, to 41cm with the cue projected at stride length). It is
important to note that despite there being an overall trend for the visual cue to evoke
improvements to gait, there was no consistent pattern delineating which of the visual
cueing spatial locations was most effective. For example, for step length, one participant
performed best at baseline (P1), three participants performed best when the laser line was
projected at the traditional location near the back wheels of the walker (P2, P4, and P6),
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one participant experienced greatest benefits from the cue at step length (P3), and one
participant performed best under the stride length condition (P5). Similar findings were
also noted for velocity and turn time. For velocity, 3 participants performed best at
baseline (P1, P2, and P6), 1 performed best with the cue placed in the traditional location
(P4), 1 at step length (P3), and 1 at stride length (P5). For turn time, 2 participants
performed best at baseline (P1, P5), 2 with the cue placed in the traditional location (P4
and P6), 1 performed equally as well across all conditions (P2), and 1 performed equally
as well at step length and stride length (P3). Gait patterns for each trial completed on the
Zeno Electronic Walkway© are presented for each participant in Figures 6a – 6f. These
images represent the influence of the visual cue and provide the means to visualize
freezing of gait.
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Figure 5a.

Figure 5b.

Figure 5c.
Figure 5. Spatiotemporal parameters of gait displayed as a function of condition and
participant: (a) Step Length; (b) Velocity; and (c) Turn Time
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Figure 6a. Participant 1
1. Baseline - No Cue Trial 1
2. Baseline - No Cue Trial 2
3. Baseline - No Cue Trial 3
4. Traditional Cue Placement Trial 1
5. Traditional Cue Placement Trial 2
6. Traditional Cue Placement Trial 3

7. Step Length Cue Placement Trial 1
8. Step Length Cue Placement Trial 2
9. Step Length Cue Placement Trial 3
10. Stride Length Cue Placement Trial 1
11. Stride Length Cue Placement Trial 2
12. Stride Length Cue Placement Trial 3
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Figure 6b. Participant 2
1. Baseline - No Cue Trial 1
2. Baseline - No Cue Trial 2
3. Baseline - No Cue Trial 3
4. Traditional Cue Placement Trial 1
5. Traditional Cue Placement Trial 2
6. Traditional Cue Placement Trial 3

7. Step Length Cue Placement Trial 1
8. Step Length Cue Placement Trial 2
9. Step Length Cue Placement Trial 3
10. Stride Length Cue Placement Trial 1
11. Stride Length Cue Placement Trial 2
12. Stride Length Cue Placement Trial 3
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Figure 6c. Participant 3
1. Baseline - No Cue Trial 1
2. Baseline - No Cue Trial 2
3. Baseline - No Cue Trial 3
4. Traditional Cue Placement Trial 1
5. Traditional Cue Placement Trial 2
6. Traditional Cue Placement Trial 3

7. Step Length Cue Placement Trial 1
8. Step Length Cue Placement Trial 2
9. Step Length Cue Placement Trial 3
10. Stride Length Cue Placement Trial 1
11. Stride Length Cue Placement Trial 2
12. Stride Length Cue Placement Trial 3
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Figure 6d. Participant 4
1. Baseline - No Cue Trial 1
2. Traditional Cue Placement Trial 1
3. Traditional Cue Placement Trial 2
4. Step Length Cue Placement Trial 1
5. Step Length Cue Placement Trial 2
6. Stride Length Cue Placement Trial 1

7. Stride Length Cue Placement Trial 2
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Figure 6e. Participant 5
1. Baseline - No Cue Trial 1
2. Baseline - No Cue Trial 2
3. Baseline - No Cue Trial 3
4. Traditional Cue Placement Trial 1
5. Traditional Cue Placement Trial 2
6. Traditional Cue Placement Trial 3

7. Step Length Cue Placement Trial 1
8. Step Length Cue Placement Trial 2
9. Step Length Cue Placement Trial 3
10. Stride Length Cue Placement Trial 1
11. Stride Length Cue Placement Trial 2
12. Stride Length Cue Placement Trial 3
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Figure 6f. Participant 6
1. Baseline - No Cue Trial 1
2. Baseline - No Cue Trial 2
3. Baseline - No Cue Trial 3
4. Traditional Cue Placement Trial 1
5. Traditional Cue Placement Trial 2
6. Traditional Cue Placement Trial 3

7. Step Length Cue Placement Trial 1
8. Step Length Cue Placement Trial 2
9. Step Length Cue Placement Trial 3
10. Stride Length Cue Placement Trial 1
11. Stride Length Cue Placement Trial 2
12. Stride Length Cue Placement Trial 3
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TUG Test
The means and standard deviations, along with individual participant data for
TUG test times are presented in Table 3. Similar to the findings reported for the
spatiotemporal parameters of gait, there were no significant differences between the time
it took participants to complete the TUG test at baseline (M= 67.83s, SD= 77.58)
compared to when visual cues were presented in the following spatial locations:
traditional cue placement (M= 40.17s, SD= 21.01); t(5)= 1.127, p = 0.31, step length cue
placement (M= 48.00s, SD= 33.18); t(5)= 0.827, p = 0.44, or stride length cue placement
(M= 49.33s, SD= 36.95); t(5)= 0.966, p = 0.37. Again, although results were statistically
non-significant, a participant substantially improved their test scores while using a visual
cue. The most prominent example of this occurrence is illustrated by participant 4 who
without the use of the visual cue took over 3.5 minutes to complete a single trial, whereas
with the visual cue their gait improved such that their best trial was completed in just over
1 minute (Table 3 and Figure 7).
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Figure 7. Time taken to complete each walking trial following the Timed-Up & Go
protocol
Walker Positioning
To determine whether the use of the visual cueing strategies altered the way
participants positioned their walkers in relation to their body, comparisons in distance
between the anterior superior iliac spine (ASIS) of the participants and their walker frame
were made between baseline and each level of the visual cue. The means and standard
deviations, along with individual participant data for the distance between walker and the
ASIS of each participant are presented in Table 4.
In contrast to the aforementioned non-significant results reported for
spatiotemporal parameters of gait and the TUG test, significant differences in walker
positioning were identified between baseline (M= 53.83, SD= 11.41) and each of the
cueing positions: traditional cue position (M= 42.17, SD= 8.28); t(5)= 3.38, p = 0.02, step
length cue position (M= 39.67, SD= 9.89); t(5)= 5.395, p = 0.003, and stride length cue
position (M= 44.00, SD= 9.88); t(5)= 4.941, p = 0.004. These results suggest that
regardless of the spatial location of the visual cue, participants positioned themselves
closer to their walker during trials wherein the Mobilaser was turned on, and positioned
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themselves further away from their walker when they ambulated in the absence of a
visual cue (Figure 8).

Figure 8. Distance between hip and walker (cm) across each condition of the visual cue.
Lastly, observations were recorded assessing the individual’s ability to ambulate
within the frame of the walker (Table 5). To safely and correctly use a wheeled walker,
the user’s feet should at minimum land within the back wheels of the walker. This
prevents the walker from getting too far in front of the individual. We observed that
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during baseline trials 4 participants (P2, P4, P5, & P6) were walking behind the walker
frame. However across each visual cue condition (traditional cue, step length cue, and
stride length cue) all of the participant’s footsteps were at least meeting the back wheels
of the walker, indicating a maintenance or improvement in the safety of walker use.

Individual Variability
Results suggest that participants demonstrated individual variability in cue
effectiveness across each of the dependent variables (Table 6).

46

Chapter 4: Discussion
The purpose of this investigation was to conduct a feasibility study to test the
protocol and clarify the components necessary to consider in the design of a future fullscale study aimed at investigating the spatial location of visual cue placement as a
strategy for managing FOG among individuals with PD.
Feasibility
The purpose of conducting a feasibility study is to identify any modifications that
need to be observed when conducting a future full scale study with respect to a novel
technique or technology. This study provided an opportunity to determine if the
components of our design were viable for use in a larger scale study (Leon, Davis, &
Kraemer, 2011). The present research was not intended to validate the efficacy of visual
cues but to determine if there is evidence to support that the location at which the cue was
presented was important to the cuing modalities overall impact. This study was also
intended to identify if the forward placed cues had any influence on walker positioning,
which is necessary for safe ambulation. This study was an essential precursor in
examining the location of cue presentation and investigating the testing protocol and
methods.
Recruitment Strategy
The method of participant recruitment was evaluated to determine whether it
would be feasible to recruit for a larger scale study from a single neurological practice
that drew from a base of approximately 400 patients. Results suggested that this single
site strategy would likely be insufficient to be able to populate a future large scale study.
Over a two month timeframe only 6 participants met the inclusion criteria and were
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enrolled in the study. Although the sample was small, the individuals who were recruited
demonstrated significant variability in regards to participant demographics and clinical
characteristics thus increasing the likelihood that if enough participants could be recruited
from this single site the results could be generalizable to the larger population. Given that
results indicated that recruitment was more difficult than originally predicted, future
studies should either expand inclusion criteria to include non-freezers, or expand
recruitment efforts to include multiple neurological practices, or utilize community based
national organizations such as the Parkinson Society Canada. However, it is important to
note that if the inclusion criteria were to be expanded to include individuals with PD and
generalized gait disturbance (i.e., not necessarily FOG) the focus of the research question
would also need to be adjusted accordingly.
Protocol Compliance
In the early stages of this study, concerns regarding the MobilaserTM and the
visibility of forward placed cues were necessary to address. Originally, it was unknown if
participants would be able to see the line of light projected at a distance equivalent to both
step and stride lengths. Visual obstructions caused by the walker (frame and or
seat/basket) and a result of the laser light reducing in intensity the further it was projected
away were factors contributing to the uncertainty of forward placed cues. The feedback
received from participants concerning the device indicated satisfaction and highlighted
the overall strengths of using this device. The clarity of the visual cue was observable at
all projected distances under the environmental conditions. The laboratory setting
consisted of slightly dimmed overhead incandescent lights along with a spotlight to help
illuminate the reflective markers used in assessing walker positioning. Additional
strengths of the Mobilaser included the overall ease of use. The device was operated by a
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single on/off switch that would require minimal training for an individual to use
independently outside of a laboratory setting. The Mobilaser also attached easily and
securely to each participants walker frame.
Study Protocol
The informed consent and execution of the study was completed in an efficient
manner requiring a minimal time commitment of 30 - 45 minutes, with no return visits.
To control for practice effects, the original study protocol called for each condition
(including baseline) to be presented in a random order to every participant. By chance,
due to this randomization the first participant was assigned to complete the baseline
condition last. Interestingly, in contrast to the study hypothesis, this participant was
observed to perform best under the baseline condition. Given these findings, it was
suggested that the participant’s performance may have been affected by a carry over
effect that resulted from the order in which the visual cues were presented. For example,
by completing baseline testing after having just completed trials that involved the visual
cues, it could not be determined whether the individual was completing a true baseline
trial (free of visual cues) or whether they were still benefiting from prior practice with the
visual cues. As a result, the experimental protocol was adapted such that baseline was
always completed first by subsequent participants, prior to the presentation of the
randomized cued conditions.
Despite each testing session only lasting 30-45 minutes, and the fact that
participants were allowed to take breaks as needed, fatigue was believed to impact
performance of some of the participants. For example, P4 required a break after only 4
trials, and was only able to complete three additional trials. Thus, in total, P4 was only
able to complete seven out of the twelve trials prior to fatigue, precluding his/her ability
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to safely complete the remaining 5 trials. Similarly, two participants (P4, P6) required
assistance in completing the final turn necessary to return to the sitting position. The
assistance provided entailed a research assistant shifting the chair on an angle, thus
facilitating the participants to sit down without completing the full turn. These results
suggest that the study protocol in its current form may be too demanding for this
population.
The participants were originally required to perform 12 walking trials (3 trials per
condition). Based on a previous study conducted (Chee et al., 2009) with regards to
cueing and PD, this was determined to be a reasonable demand to ask of participants.
However, based on the performance of two participants who demonstrated fatigue, the
original testing protocol may be too challenging for individuals with severe FOG to
complete. One likely explanation that may account for why some participants were
unable to complete all testing could be related to the manner in which each trial began.
For instance, the demands of sitting and standing during the TUG increased the demand
of each trial. For future investigations of this nature modifications could be made to the
study protocol to help minimize fatigue. One possibility would be to reduce the number
of walking trials, another option would be to remove the sitting and standing component
of the Timed-Up & Go test. This alteration would be appropriate in minimizing any
extraneous exertion caused by rising from a chair numerous times. Similarly, raising or
lowering into a seated position is not a known trigger of FOG (Contreras & Grandas,
2012; Lamberti et al, 1997; Rahman et al., 2008) and therefore suggests that the TimedUp & Go test may not be the most appropriate measure to use when studying this
phenomenon.
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Safety concerns while working with a population that has known gait disturbances
and increased risk of falling were addressed by using a Solo Step safety system. While the
device was found to be comfortable to wear, easy to employ, and appropriately followed a
track that ran the length of the walking trial, the harness height was not retractable. This
proved to be a challenge in that a research assistant was required to manually adjust the
harness system each time participants stood up and sat down. If not completed, and a
participant fell, they would have been prevented from hitting the ground, but placed in a
very awkward position that could have still resulted in injury. Therefore, to ensure safety
a research assistant was required to walk beside the participant acting as a spotter ready to
remove the slack in the harness strap, if the participant were to fall. Unfortunately, it is
possible that having an individual walk beside the participants may have served as a
distraction away from the visual cue. In the future this concern could be avoided by
incorporating a self-retracting fall prevention harness, a device used in construction and
regulated by the Canadian Standards Association (Infrastructure Health & Safety
Association, 2013). Alternatively, as previously suggested, if the sit and stand portion of
the trials were removed this would eliminate the need for a retractable device and the
SOLO Step safety device could be used for further study.
It is believed that anxiety/stress played a greater role in the study than originally
predicted. Stressful environments are a known trigger of FOG (Contreras & Grandas,
2012; Lamberti et al, 1997; Rahman et al., 2008), and this could have been better
controlled within the current protocol. To minimize the amount of stress/anxiety
experienced by participants, each individual was provided with an opportunity to walk
around the lab and acclimatize to the testing setup. Despite this opportunity, one
participant (P4) reported that they felt some anxiety during the first half of the testing
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session as they were unsure of their perceived performance during the trials (i.e., they
were concerned they were not meeting the expectations of the research team). Following
a short break, wherein the individual was provided with positive reinforcement, the
individual indicated that they were more relaxed and wanted to continue. The effect on
performance that resulted was evidenced by a substantial improvement within their
quality of gait, as demonstrated in Figure 6d.
Due to current knowledge relating to the role of anxiety and stress on FOG,
incorporation of a longitudinal study design may be warranted. For example, a study by
Rahman et al. (2011) that evaluated fear of falling (FOF), a form of anxiety relating to the
fear of potentially falling, determined that individuals experiencing gait disturbances
(including FOG) also experienced increased levels of FOF. In terms of the current study,
the participants recruited may be experiencing anxiety due to their familiarity with
freezing. This could have been exacerbated by a new environment and the knowledge that
their gait was being evaluated. Despite the reassurance that each participant received,
their experience with gait disturbances may have indicated a predisposition to anxiety.
Further exploration would need to be conducted to determine effective ways to reduce the
anxiety and stress perceived by the participants. For instance, individuals could become
accustomed to the testing environment and using visual cueing (ie. multiple testing
sessions or the ability to practice prior to the researchers presence), in hopes of decreasing
their anxiety. However, by integrating a longer practice period or expanding the number
of testing sessions to put the participants at ease, this may exacerbate concerns related to
fatigue and an increase in testing time.
Finally, the technologies used to capture and analyze the data within this study
were being employed for the first time in this research lab. As a result, an important
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component of this study was determining the utility of this equipment within this context.
The practicality of using the Zeno Electronic Walkway needs to be addressed in further
detail due to shortcomings that were experienced with analyzing the data. The
manufacturer specified the carpets ability to quantify the turning aspects of walking as
well as its capacity to analyze freezing episodes. However, the ProtoKinetics Movement
Analysis Software, which is used in conjunction with Zeno Walkway, had difficulty
isolating the overlapping footsteps during turning and extreme freezing. For example, P3
completed the walking trials in an “out and back” manner. The participant retraced their
steps making it difficult to separate the footsteps, particularly during the turning portion
of the trial. Following assistance from a company representative, the problem could not
be resolved. As a result, the footstep pattern could only be quantified during the straightline walking segments of each trial. Consequently, the analysis of turning relied solely on
the time it took to turn which may not be the most sensitive measure to express a change
in the participants turning capabilities. For example, by only analyzing the time taken to
turn, the carpet was unable to analyze information regarding the number of steps taken to
turn or the relative arc of the turn. These variables may be particularly important to
consider given that observable changes in gait patters were noted for 2 out of the six
participants. Specifically, P1 demonstrated a much narrower turn during stride length
visual cue use (Figure 6a), and, P5 required fewer steps to turn using the traditional cue
(Figure 6e). In light of these unexpected limitations, the Zeno walkway may not be the
most appropriate device to use to examine these outcome measures. Instead, future
research in this area may require the use of a 3D motion capture system.
Kinovea movement analysis software has been determined to be a feasible method
in which to analyze the videotaped trials. The program is free to download, user friendly,
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and relatively simple to become familiar with. One limitation identified was the
program’s inability to continuously track the distance between two markers (B and C) in
real time. To overcome this limitation for the current study, a distance measurement
during the straight walking portion of each trial at a predetermined location was taken.
The location ensured participants were directly in line with the video camera. Clinically,
Kinovea could be a useful tool due to its readily available nature but may not be the most
appropriate with regards to real time gait analysis.
Improvement in Walker Positioning
Previous research that evaluated the use of rolling walkers by older adults
indicated that 50% of participants assumed a forward leaning posture during walker use
(Liu, 2009). As a result of the posture adopted, the user’s feet did not maintain a safe
position between the rear wheels of the walker, thus increasing the risk of a fall (Liu,
2009). Therefore while walkers are designed to provide support to help with balance and
minimize falls risk, if not used properly they may have a negative impact on the user’s
posture that in turn may exacerbate the symptom they were originally prescribed to assist
with. Consistent with these previous literature findings the current study demonstrated
that during the baseline condition, 4 of 6 participants adopted a forward leaning posture
and did not walk within the walker frame. However, with the application of visual cueing,
in each prearranged location, all participants changed their positioning in relation to the
walker. With visual cueing each participant significantly decreased the distance between
themselves and the walker and safely walked within the walker frame, thus decreasing the
potential for falls. It is unclear why participants adopted a safer position in relation to the
walker when using the visual cues. One possibility could be that by focusing attention on
the visual cues participants were more aware of their body positioning with regards to the
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walker. To examine this possibility, future studies could incorporate a qualitative
component that asks participants to comment on their experience of using the cues in
relation to walker positioning.

Rationale for Non-Significant Findings
The purpose of this study was to determine the feasibility of the methods and
study components. Therefore, not finding statistical significance within the
spatiotemporal parameters of gait and the Timed-Up & Go test results was expected due
to the small sample from which the data were collected. Despite non significant findings,
participants did demonstrate a range of performance improvements across the outcome
measures thus suggesting this line of inquiry is appropriate for further study. The pattern
of improvement varied among individuals thus speaking to the diversity of our sample
characteristics and the variable nature of PD (Jankovic, 2008).
The results of this study indicated that the traditional cue was the most effective
cue in terms of increasing step length (4 of 6 participants). This was consistent with
previous cueing studies conducted by Morris et al., (1996) and Jiang & Norman (2006).
However, with regards to walker positioning, results suggest that visual cues presented
60-62cm (step length) in front of the walker, were most effective in decreasing the
distance between the participant and their walker. Through improving walker positioning,
the forward leaning posture of participants, that is commonly adopted when a walker is
too far in front of the individual, is effectively decreased. This study demonstrates the
possibility of a trade-off between the effectiveness of a visual cue in the traditional
position compared with in the step length position. The step length position, while less
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effective (in terms of improving step length) appears safer, regarding walker positioning
and environmental awareness.
Visual cueing and the spatial location of its presentation may be highly
individualized in terms of managing gait disturbance. Consistent with the study by
Rahman et al., (2008) where 31.5% of their sample improved mobility with use of the
visual cues and a lesser percent expressed similar benefits through tactile and auditory
cues. The positioning of visual cues may also be preferential to individuals. Findings
from the current study indicate that presenting a visual cue in a specified single spatial
location is not optimal for everyone. Further research is needed to determine the
individualized characteristics that may predict where the optimal visual cue location is for
each specific user.
Study Limitations
The results of the study are promising and indicate the need for further research;
however, some limitations warrant attention in the interpretation of findings as well as
necessary modifications for future design.
This was designed as a feasibility study and therefore the small highly variable
sample size (N=6) was limited in statistical power. Similarly, the nature of PD is variable
across the rate of progression and the symptoms experienced from person to person. It is
therefore difficult to quantify improvement and establish a standard baseline across
individuals (Jankovic et al., 1990).
The study was limited in terms of there being no known clinically meaningful
difference regarding the outcome measures of interest within a PD population. Studies
have been done regarding meaningful change in older adults but little has been done with
PD. In order to address the results of this study, results were compared to those of healthy
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older adults without neurologic impairment. For example, according to Ko et al. (2011),
the average normal stride length of male and female older adults is 123 and 119cm,
respectively (Ko et al., 2011). To assess if the use of visual cueing helped to normalize
step length, the changes in this variable were compared to the values established with
individuals without PD. Moreover, due to the lack of information regarding what is
considered a minimally important change, a limitation is apparent.
For instance, in a study conducted by Perera, Mody, Woodman, & Studenski
(2006), they investigated a meaningful and substantial change within the physical
performance of older adults. Their initial estimate regarding a substantial meaningful
change in gait speed was 10cm/s in older adults, and they deemed 5cm/s as a small
meaningful change (Perera et al., 2006). In a subsequent study by Verghese, Holtzer,
Lipton, & Wang (2009), 10-unit changes in performance was applied to a variety of gait
markers including cadence, stride length, swing, double support, stride length variability,
and swing time variability. They reported that changes equivalent to 10-unit changes were
considered meaningful based on Perera et al., (2006) to make their observations clinically
intuitive despite only having information regarding gait speed.
Working with a population that is considerably non-normal in terms of gait
performance we cannot appropriately apply this method without determining the
relevancy of clinically and minimally important differences. For example, the average
gait speed in the study by Verghese et al., (2009) was 92.8 ± 24.1 cm/s. They determined
that slow gait speed was operationally defined as that of less than 70cm/s (Verghese et al.,
2009). The results of the present study observed mean velocity at baseline to be 51.17
cm/s and visual cue use mean gait speed ranged from 48.50 cm/s to 51.67 cm/s. With
drastic differences across the sample populations’ performance comparisons cannot
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justifiably be made to the same measures. Further research is needed to determine a
clinically or minimally significant difference for this population as well as determining an
effect size estimate for sample size calculation. The current feasibility research is not able
to provide a meaningful effect size estimate due to the imprecise and non-generalizable
nature of data collected from small samples (Leon et al., 2011).
Limitations were found in terms of the dimensions (4ft by 10ft) of the Zeno
Electronic Walkway used during the trials. The width of the mat posed a problem in terms
of the requiring a tight turning radius be performed by participants which is difficult
while operating a rolling walker. The constraints this placed on participants may have
played a role in the speed at which they tried to complete the turn.
Simultaneously the length of the mat also was a limitation of the study. To insure
the turning portion of the TUG test remained on the mat participants began the test 1
metre behind the mat. Due to the dimensions of the Zeno Walkway, the participants were
initiating gait off the mat thus data were not captured on FOG that occurred during this
portion of the trial. According to the Zeno Walkway output only 2 out of 6 participants
visibly froze. The majority of the participants actually demonstrated FOG upon the
initiation of gait and this was not captured by the Zeno Walkway or through video.
Videotaping was primarily used to capture the straight walking portions of the trial in
order to analyze walker positioning and posture. To accomplish this, the camera was
placed on a tripod to maintain a stable image but in doing so it prevented the recording of
the entire trial. As a result, the ability to capture data when participants were off the mat
at the start and end of each trial was limited.
Limitations encountered during analysis had to do with the inability of the
Kinovea software to continuously track distance between participant and walker in real
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time. Although a standardized position within each trial was used to capture this data it
would be more appropriate to determine the mean distance over the duration of the trial.
As mentioned earlier the inability of the Zeno Electronic Walkway to accurately capture
turning and freezing during walking trials was a weakness of the study. Further research
must be done to determine a more precise measurement of these elements.

Future Directions
An original portion of the study included the use of Electromyography (EMG) to
assist with the understanding of FOG. EMG quantifies the electrical activity produced by
skeletal muscles providing a means to observe the effect of FOG and PD at the level of
the muscle (Konrad, 2006). EMG was to be incorporated within this study to record any
effect that the visual cue may have had on the gait of participants, such as the timing of
muscle activation and strength of muscle contraction. Nieuwboer et al., (2004) compared
the EMG profiles of the lower limbs in 11 individuals with PD. This was done to analyze
the temporal aspects of gait prior to freezing compared with a voluntary stop as well as a
normal stride. The study observed significantly abnormal timing within the EMG
recordings from the tibialis anterior (TA) and gastrocnemius (GS) muscles prior to
freezing. Results indicated that the TA was prematurely activated 72.6% of the time prior
to freezing and the GS muscle activity was also initiated and inhibited earlier in the gait
cycle prior to freezing. The study concluded that the overall reduced EMG activity
resulting from a shortened muscle activation period contributed to slower movements, a
decrease in step length, and ultimately interrupted movement (Nieuwboer et al., 2004).
For the purpose of this study, EMG was to reveal the effects of visual cues specifically
with respect to distal and proximal lower limb muscle activity patterns preceding the
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freeze-provoking aspects of walking trials. However, upon beginning of the initial testing
session with the first participant technical problems occurred with the EMG device and it
was removed from future trials. With the EMG system not functioning, the ability to
capture participant trunk angle via an inclinometer was also lost. It is recommended that
EMG and Inclinometer be used in further studies to broaden the current knowledge of
FOG.
The results of this study lead to the conclusion that several modifications to the
study protocol could be made to better capture the influence of visual cueing. For instance
a case based ABA design would be an appropriate means to visualize any carryover
effects. It is suspected that some results may have been washed out due the effects of one
experimental condition affecting another. Incorporating an ABA design would allow for
the comparison of baseline values pre and post visual cueing conditions thus providing
for the identification of carryover effects. Alternatively, as described earlier, the
integration of a longitudinal study design would be appropriate to assist with individuals
becoming accustomed to the testing environment and the use of visual cueing. This would
effectively deal with any anxiety or stress causing aspects of a new environment or
management strategy.
Given that current findings indicate that individuals respond differently to visual
cues and their spatial locations, it is recommended that future research focus on
developing a screening tool to enable clinicians to predict which cue placement would be
most appropriate for specific individuals. Lastly, the inclusion of participant journals to
capture the participants perspective of using visual cues in various locations would
summarize aspects of the study that are not identified by quantitative results alone.
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Chapter 5: Conclusion
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder
(Samii et al., 2004) with an increasing prevalence among the current aging population
(Lees et al., 2009; de Rijk et al., 1995). The disease is characterized by bradykinesia,
resting tremors, postural instability, and rigidity (Benatru et al., 2008); however, the nonmotor symptoms are just as troubling in terms of the impact on quality of life (Karlsen et
al., 2000). Accompanying the primary features of PD, freezing of gait (FOG), festination
and a stooped forward leaning posture (Jankovic, 2008; Lees e al., 2009; Yarnall et al.,
2012) contribute largely to the increased risk of falling and loss of independence within
this population (Bloem et al., 2004; Giladi et al., 1997).
Treatment of PD focuses on symptom management (Lees et al., 2009) and
primarily relies on dopamine replacement therapy, known as Levodopa (Cotzias et al.,
1969). While drug therapy is effective in the management of many motor symptoms,
Levodopa is limited in its ability to ameliorate FOG and postural instability (Bowes et al.,
1990; Levy-Tzedek et al., 2011). The uses of external cueing, including tactile, auditory,
and visual cue modalities, have shown potential as a non-pharmacological option to
improve quality of movements (Rochester et al., 2005). Research suggests that visual
cueing is most effective at reducing the occurrence of freezing (Rahman et al., 2008).
The MobilaserTM is a promising dynamic visual cue that emits a red line of light
on the ground for the user to step over (In Step Mobility, 2009). The device provides a
solution to the previously effective, yet impractical, static transverse lines marked on the
floor. However, to step over the prompt created by the MobilaserTM, the user must direct
their attention towards their feet. This is known to decrease gait speed, decrease step
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length, increase the risk of obstacle collisions due to lack of environmental awareness
(Matthis & Fajen, 2013; Marigold & Patla, 2008) and interfere with peripheral vision
which is important in gait control (Patla, 1998).
The current research suggests that forward placed cues may be a feasible
alternative therapy. Significant improvements in walker positioning occurred in
participants regardless of the spatial location of the visual cue. Despite not finding
statistically significant improvements in the spatial temporal parameters of gait, the
performance changes in some participants indicated the capacity for further development.
Positive participant feedback, along with the strengths and user friendly nature of the
MobilaserTM device, provided additional rationale to further the investigation of forward
placed cues.
In conclusion, although forward placed visual cueing indicates potential as a novel
management strategy of FOG and gait disturbance, future research is required on a larger
scale before it can be put into practice.
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Appendix A: LETTER OF INFORMATION
The influence of external cueing on balance, freezing of gait and falls among
individuals with Parkinson's disease
Phase 2
INVESTIGATORS:
Dr. Jeffrey Holmes, OT Reg.(Ont), PhD
Dr. Mary Jenkins, BSc (PT), MD, FRCPC

(519) 661-2111 x88967
(519) 685-8300 x33404

You are invited to participate in a research study in which we will examine the influence
of using a visual cueing device that projects a beam of light on the floor (mobilaser) on
freezing of gait (FOG), and falls among individuals with Parkinson’s disease (PD).
The purpose of this letter is to provide you with information required for you to make an
informed decision regarding participation in this research.
Background
Freezing of gait, is a troublesome motor symptom of Parkinson’s disease with a
significant impact on fall risk and quality of life. Studies suggest that approximately 30%
of individuals with PD experience FOG within 5 years and nearly 60% report FOG after
10 years. Although medication improves some of the symptoms of slowness and rigidity,
it is only minimally effective in treating FOG or reducing fall risk. Therefore, a better
understanding of alternative treatment strategies is needed to manage these symptoms.
Inclusion and Exclusion Criteria
We plan to test a total of 30 participants. In order to be eligible for participation, you must
be at least 50 years of age, have a clinical diagnosis of PD with a history of freezing of
gait and falls, are capable of walking 20 feet with or without the use of an assistive device,
able to stand independently for 5 minutes at a time, have functional vision that allows you
to see the visual cue (laser beam of light projected on the ground), and are able to
complete a daily freezing of gait/falls journal.
You will not be eligible to participate if you report experiencing major back or lower limb
pathology that may influence standing balance or gait, if you are unable to complete a
daily freezing of gait/fall journal, or if you cannot see the visual cue.

83

Description of Research
If you agree to participate in this research study you will be asked to participate in two
gait laboratory testing sessions wherein your walking patterns will be assessed. You will
also be asked to take the visual cueing device home with you and use it on a regular basis
for 12 consecutive weeks. A description of the activities that you will be asked to
participate in during both the laboratory sessions and during the 12 week home based trial
period is provided below.
Both of the laboratory based testing sessions will be identical and will take place in the
Interdisciplinary Movement Disorders Laboratory, Room 1545 Elborn College, at the
University of Western Ontario. To measure your walking pattern, you will be asked to
perform nine walks at your normal pace down a GAITRite instrumented carpet, a device
with approximately 16,000 sensors built into its surface. These sensors feed information
to an attached computer, and this information is utilized to provide us with information
concerning your walking (e.g., the length of each step you take, the speed at which you
walk, etc.). The nine walks will be divided such that you complete three walks under each
of the following conditions: i) no visual cue, ii) visual cue projected directly in front of
your feet, and iii) visual cue projected 1 – 2 meters in front of your feet. The testing order
of cue presentation will be randomly assigned. To help you become familiar with the cue
location, you will be asked to walk around the lab at a self-selected pace, for three
complete circuits prior to the start of testing within each condition.
You will also be asked to complete the Timed Up and Go test nine times as follows: three
times with no visual cue, three times with the visual cue projected directly in front of your
feet, and three times with the visual cue projected 1 – 2 meters in front of your feet. For
this test you will be asked to stand up from a chair, walk three meters, turn around, walk
back to the chair and sit down while walking at a comfortable pace
While you are completing the previously outlined tests of gait, we will be recording
muscle activity patterns from four muscles in your legs using wireless surface
electromyography. To record this activity four sets of surface electrodes will be placed on
each of your legs, two sets on the front, and two sets on the back. This test will provide
us with information about what muscles are activated in your legs.
The final task that you will be asked to complete during each of the laboratory sessions
will be to fill out a short freezing of gait questionnaire.
Twelve Week Intervention
At the end of the first laboratory based testing session you will be randomly assigned to
one of the following three groups: i) visual cue projected directly in front of feet (test
group 1), ii) visual cue projected 1 – 2 meters in front of feet (test group 2), or iii) no
visual cue (control group). If you are assigned to either test group you will be provided
with a visual cueing device (mobilaser) for your personal use over the course of the 12
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week study. During the 12 week period you will be asked to use the visual cueing device
on a regular basis throughout the course of each day. If you are assigned to the control
group you will be asked to complete your daily activities as usual (i.e., without using an
external cueing device). During the 12 week time period, all study participants (regardless
of which group you are assigned to) will be asked to keep a daily journal with information
pertaining to hours of use, and number of FOG episodes or falls that occur. To help
remind you to complete the daily journals you will receive a weekly telephone call by a
member of the research team throughout the duration intervention.
Following the 12 week intervention period, you will be asked to return to the laboratory
for the second laboratory based session to repeat the same gait testing completed earlier in
the study. Upon study completion, participants who were assigned to the control group
will be given the opportunity to take a Mobilaser unit home with them to use for a trial
period.
The tasks involved in each testing session will take approximately 60 minutes to complete,
and should involve no risks or discomforts beyond those normally experienced by you in
performing normal everyday walking tasks.
Potential Benefits
Although you may not experience any direct benefits from participating in this research,
we anticipate that you will experience an improvement in your walking, and a reduction
in the frequency in which you experience freezing episodes, thus your participation may
increase your ability to participate within the community. In addition, we anticipate that
the results obtained through this study will provide us with valuable information
concerning the benefits of implementing visual cueing strategies as a clinical
rehabilitation tool.
Potential Risks or Discomforts
There is a small risk in this study that you may experience a temporary loss of balance
while performing the tasks used to assess your gait. To minimize the risk of injury you
will complete study tasks while wearing a balance support harness. There is also a small
risk that you may experience discomfort when the electrodes used to measure your
muscle activity are removed. It is believed such discomfort will not be greater then that
which is experienced when removing a band-aid.
Voluntary Participation and Protection of Information
Your participation in this research project is voluntary. You may refuse to participate,
refuse to answer any questions, and you may withdraw your participation at any time with
no effect on the future healthcare that you receive or future participation in activities
sponsored by the University. If you withdraw your participation in the study before the
conclusion of data collection, your data will be destroyed. In order to assure complete
confidentiality, no identifying information will be attached to the data collected in this
study. The only record of your name that will be retained will be on the attached consent
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form, and this information will be stored in a locked file cabinet, within a locked room,
that is (in turn) inside the Interdisciplinary Movement Disorders Laboratory (which
remains locked at all times). This information will not be linked, in any way, with the
study information. This also means that your data may not be withdrawn from the study
after the testing session is concluded, and the information is entered into the computer. If
the results of this study are published, your name will not be used, and no information
that discloses your identity will be released or published without your explicit consent to
the disclosure. Electronic data collected during the course of this study will be kept
indefinitely.
You will not receive remuneration for participation in this study.
Further Questions
If you have any questions about this research project, please contact the principal
investigators, Dr. Jeffrey Holmes, at (519) 661-2111 x88967, or by email at
jeff.holmes@uwo.ca. If you have any questions about your rights as a research participant,
or the conduct of this study, you may contact the Office of Research Ethics, (519) 6613036, email: ethics@uwo.ca, or Dr. David Hill, Scientific Director, Lawson Health Research
Institute (519) 667-6649. You are not waiving any legal rights by signing the attached
consent form. This letter is yours to keep.
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Appendix B: CONSENT TO PARTICIPATE IN RESEARCH
FORM
The influence of external cueing on balance, freezing of gait and falls among
individuals with Parkinson's disease
Phase 2
Please sign this form to indicate that you agree with the following statement:
I have read the Letter of Information, have had the nature of the study explained to me,
and I agree to participate. All questions have been answered to my satisfaction.

Participant (Printed Name): ________________________________________________
Participant (Signature): ____________________________________________________
Person Obtaining Informed Consent (Printed Name): ____________________________
Person Obtaining Informed Consent (Signature): _______________________________
Date: ____________________________
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Appendix C: RESEARCH ETHICS BOARD APPROVAL
FORM
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Appendix D: Unified Parkinson Disease Rating Scale
Subsection III
Unified Parkinson’s disease Rating Scale III. Motor Examination
(Fahn & Elton, 1987)
18. Speech
0 = Normal.
1 = Slight loss of expression, diction and/or volume.
2 = Monotone, slurred but understandable; moderately impaired.
3 = Marked impairment, difficult to understand.
4 = Unintelligible.
19. Facial Expression
0 = Normal.
1 = Minimal hypomimia, could be normal "Poker Face".
2 = Slight but definitely abnormal diminution of facial expression.
3 = Moderate hypomimia; lips parted some of the time.
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted
1/4 inch or more.
20. Tremor at rest (head, upper and lower extremities)
0 = Absent.
1 = Slight and infrequently present.
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently
present.
3 = Moderate in amplitude and present most of the time.
4 = Marked in amplitude and present most of the time.
21. Action or Postural Tremor of hands
0 = Absent.
1 = Slight; present with action.
2 = Moderate in amplitude, present with action.
3 = Moderate in amplitude with posture holding as well as action.
4 = Marked in amplitude; interferes with feeding.
22. Rigidity (Judged on passive movement of major joints with patient relaxed in sitting
position. Cogwheeling to be ignored.)
0 = Absent.
1 = Slight or detectable only when activated by mirror or other movements.
2 = Mild to moderate.
3 = Marked, but full range of motion easily achieved.
4 = Severe, range of motion achieved with difficulty.
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23. Finger Taps (Patient taps thumb with index finger in rapid succession.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in
movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing
movement.
4 = Can barely perform the task.
24. Hand Movements (Patient opens and closes hands in rapid succesion.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in
movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing
movement.
4 = Can barely perform the task.
25. Rapid Alternating Movements of Hands (Pronation-supination movements of hands,
vertically and horizontally, with as large an amplitude as possible, both hands
simultaneously.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in
movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing
movement.
4 = Can barely perform the task.
26. Leg Agility (Patient taps heel on the ground in rapid succession picking up entire leg.
Amplitude should be at least 3 inches.)
0 = Normal.
1 = Mild slowing and/or reduction in amplitude.
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in
movement.
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing
movement.
4 = Can barely perform the task.
27. Arising from Chair (Patient attempts to rise from a straight backed chair, with arms
folded across chest.)
0 = Normal.
1 = Slow; or may need more than one attempt.
2 = Pushes self up from arms of seat.
3 = Tends to fall back and may have to try more than one time, but can get up without
help.
4 = Unable to arise without help.
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28. Posture
0 = Normal erect.
1 = Not quite erect, slightly stooped posture; could be normal for older person.
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side.
4 = Marked flexion with extreme abnormality of posture.
29. Gait
0 = Normal.
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or
propulsion.
2 = Walks with difficulty, but requires little or no assistance; may have some festination,
short steps, or propulsion.
3 = Severe disturbance of gait, requiring assistance.
4 = Cannot walk at all, even with assistance.
30. Postural Stability (Response to sudden, strong posterior displacement produced by
pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is
prepared.)
0 = Normal.
1 = Retropulsion, but recovers unaided.
2 = Absence of postural response; would fall if not caught by examiner.
3 = Very unstable, tends to lose balance spontaneously.
4 = Unable to stand without assistance.
31. Body Bradykinesia and Hypokinesia (Combining slowness, hesitancy, decreased
armswing, small amplitude, and poverty of movement in general.)
0 = None.
1 = Minimal slowness, giving movement a deliberate character; could be normal for
some persons. Possibly reduced amplitude.
2 = Mild degree of slowness and poverty of movement which is definitely abnormal.
Alternatively, some reduced amplitude.
3 = Moderate slowness, poverty or small amplitude of movement.
4 = Marked slowness, poverty or small amplitude of movement.
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Appendix E: Modified Hoehn and Yahr Scale
(Hoehn &Yahr, 1998)
Modified Hoehn and Yahr Staging
STAGE 0 = No signs of disease.
STAGE 1 = Unilateral disease.
STAGE 1.5 = Unilateral plus axial involvement.
STAGE 2 = Bilateral disease, without impairment of balance.
STAGE 2.5 = Mild bilateral disease, with recovery on pull test.
STAGE 3 = Mild to moderate bilateral disease; some postural instability; physically
independent.
STAGE 4 = Severe disability; still able to walk or stand unassisted.
STAGE 5 = Wheelchair bound or bedridden unless aided.
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Appendix F: Freezing of Gait Questionnaire (FOGQ)
1. During your worst state—Do you walk:
0
1
2
3
4

Normally
Almost normally—somewhat slow
Slow but fully independent
Need assistance or walking aid
Unable to walk

2. Are your gait difﬁculties affecting your daily activities and independence?
0
1
2
3
4

Not at all
Mildly
Moderately
Severely
Unable to walk

3. Do you feel that your feet get glued to the ﬂoor while walking, making a turn or when
trying to initiate walking (freezing)?
0
1
2
3
4

Never
Very rarely—about once a month
Rarely—about once a week
Often—about once a day
Always—whenever walking

4. How long is your longest freezing episode?
0
1
2
3
4

Never happened
1–2 s
3–10 s
11–30 s
Unable to walk for more than 30 s

5. How long is your typical start hesitation episode (freezing when initiating the ﬁrst step)?
0
1
2
3
4

None
Takes longer than 1 s to start walking
Takes longer than 3 s to start walking
Takes longer than 10 s to start walking
Takes longer than 30 s to start walking
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6. How long is your typical turning hesitation: (freezing when turning)
0
1
2
3
4

None
Resume turning in 1–2 s
Resume turning in 3–10 s
Resume turning in 11–30 s
Unable to resume turning for more than 30 s
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